Environmental hazard assessment of Venezuelan equine encephalitis virus vaccine candidate strain V3526.
A hazard assessment of Venezuelan equine encephalitis (VEE) virus sub-types and vaccine candidates was performed according to standard risk assessment procedures. Data from published literature demonstrates a considerable degree of safety of V3526 when compared to TC-83 vaccine, the protective measure that has been used to protect laboratory workers for over four decades. V3526 is a new recombinant vaccine candidate that is a vastly different product with a diminished hazard to public health and the general environment. A weight-of-evidence (WOE)-based scheme was employed to assign weights for relevance, quality, and adequacy of evidence in published literature on medical pathology, epidemiology, pre-clinical investigational studies, and environmental studies. The results of this assessment indicated that V3526 has a low adverse impact on public health and the general environment. Although there are currently no human infectivity or pathogenicity data for V3526, existing evidence from published experimental animal studies reveals a diminished hazard for environmental transmission and distribution. Recently, the US Centers for Disease Control and Prevention (CDC) excluded V3526 from select agent requirements set forth under the Health and Human Services (HHS) regulations in Title 42 C.F.R. Part 73 and the US Department Agriculture (USDA) regulations set forth in Title 7 C.F.R. Part 331 and Title 9 C.F.R. Part 121. This paper summarizes the background, rationale, and hazard analysis used for assessing the environmental hazard of the VEE vaccine candidate strain V3526.
Rao
Venkat
V
DynPort Vaccine Company LLC, 6101 Stevenson Avenue, Alexandria, VA 22304, USA. vrao4@csc.com
Hinz
Matthew E
ME
Roberts
Brian A
BA
Fine
Donald
D
D000818:Animals; D004666:Encephalitis Virus, Venezuelan Equine / Q000276:immunology / Q000502:physiology*; D004685:Encephalomyelitis, Venezuelan Equine / Q000473:pathology; D011634:Public Health; D018570:Risk Assessment; D014481:United States; D014489:United States Occupational Safety and Health Administration; D014614:Vaccines, Synthetic / Q000009:adverse effects / Q000276:immunology / Q000592:standards; D014765:Viral Vaccines / Q000009:adverse effects* / Q000276:immunology / Q000592:standards* / Q000627:therapeutic use
D014614:Vaccines, Synthetic; D014765:Viral Vaccines